Search results
Results from the WOW.Com Content Network
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...
In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer in 2010) for the treatment of FAP based on clinical trial data. Tafamidis (20 mg once daily) slowed the progression of FAP over a 36-month ...
In another key category, our Vyndaqel family of products achieved continuing momentum with 90% year-over-year growth in the U.S. ... It is prescribed to millions of patients, and we continue to ...
On the other hand, Pfizer's Vyndaqel is the first drug used for treatment of FAP, one of two forms of ATTR. The product is approved only in Europe. Prior to Vyndaqel, liver transplantation was the ...
This combination has quickly become the most prescribed first-line treatment in the U.S. for locally advanced metastatic urothelial cancer. ... VYNDAQEL is reimbursed in 44 markets right now and ...
The Vyndaqel family of drugs recorded a remarkable 61% growth, aided by increased patient diagnoses and heightened demand. Meanwhile, Comirnaty revenue plummeted by 37%, reflecting COVID-19's ...
Amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. Trading not far from its lowest split-adjusted level in thirteen years, the stock is an ...
(Reuters) -Alnylam Pharmaceuticals said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration ...